Table 1.

Summary of FDA-approved CAR T cell therapies for B cell malignancies and multiple myeloma.

Company name Brand name Generic name	Date of approval	Target antigen/ Antibody	Hinge/ transmembrane	Costimulatory domains	Vector/ promoter	Targeted cancers	Pivotal trial	No. of Patients	Outcomes	References
Novartis Kymriah Tisagenlecleucel	Aug 30, 2017	CD19 Mouse FMC63	CD8α/CD8α	4-1BB + CD3ζ	Lentiviral EF1α	R/R CAYA B-ALL	ELIANA (NCT02228096)	75	81% overall remission rate	(58)
Kite Yescarta Axicabtagene ciloleucel	Oct 18, 2017	CD19 Mouse FMC63	CD8α/CD8α	CD28 + CD3ζ	Gammaretroviral LTR	R/R LBCL	ZUMA-1 (NCT02348216)	108	58% complete response	(59)
Kite Tecartus Brexucabtagene autoleucel	Jul 24, 2020	CD19 Mouse FMC63	CD28/CD28	CD28 + CD3ζ	Gammaretroviral LTR	R/R MCL	ZUMA-2 (NCT02601313)	68	67% complete response	(61)
Juno Breyanzi Lisocabtagene maraleucel	Feb 5, 2021	CD19 Mouse FMC63	IgG4/CD28	4-1BB+ CD3ζ	Lentiviral EF1α	R/R LBCL	Transcend NHL001 (NCT02631044)	269	53% complete response	(60)
Bluebird Abecma Idecabtagene vicleucel	Mar 26, 2021	BCMA Mouse BB2121	CD8α/CD8α	4-1BB+ CD3ζ	Lentiviral MND	R/R MM	KarMMa (NCT03361748)	128	33% complete response	(63)
J&J and Legend Carvykti Ciltacabtagene autoleucel	Feb 28, 2022	BCMA dual camel single-domain antibodies	CD8α/CD8α	4-1BB + CD3ζ	Lentiviral EF1α	R/R MM	CARTITUDE-1 (NCT03548207)	97	82.5% complete response	(64)

R/R, relapsed or refractory. CAYA, children and young adults. LBCL, large B-cell lymphoma. MCL, mantle cell lymphoma. MM, multiple myeloma.